Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
- PMID: 12162811
- DOI: 10.1089/104303402760128513
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
Abstract
Intramuscular injection of an adeno-associated virus (AAV) vector has resulted in vector dose-dependent, stable expression of canine factor IX (cF.IX) in hemophilia B dogs with an F.IX missense mutation (Herzog et al., Nat. Med. 1999;5:56-63). The use of a species-specific transgene allowed us to study risks and characteristics of antibody formation against the therapeutic transgene product. We analyzed seven dogs that had been injected at a single time point at multiple intramuscular sites with varying vector doses (dose per kilogram, dose per animal, dose per site). Comparison of individual animals suggests an increased likelihood of inhibitory anti-cF.IX (inhibitor) development with increased vector doses, with dose per site showing the strongest correlation with the risk of inhibitor formation. In six of seven animals, such immune responses were either absent or transient, and therefore did not prevent sustained systemic expression of cF.IX. Transient inhibitory/neutralizing anti-cF.IX responses occurred at vector doses of 2 x 10(12)/site, whereas a 6-fold higher dose resulted in a longer lasting, higher titer inhibitor. Anti-cF.IX was efficiently blocked in an eighth animal that was injected with a high vector dose per site, but in addition received transient immune suppression. Inhibitor formation was characterized by synthesis of two IgG subclasses and in vitro proliferation of lymphocytes to cF.IX antigen, indicating a helper T cell-dependent mechanism. Anti-cF.IX formation is likely influenced by the extent of local antigen presentation and may be avoided by limited vector doses or by transient immune modulation.
Similar articles
-
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.Gene Ther. 2005 Oct;12(19):1453-64. doi: 10.1038/sj.gt.3302539. Gene Ther. 2005. PMID: 15889137
-
Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.Mol Ther. 2000 Mar;1(3):225-35. doi: 10.1006/mthe.2000.0032. Mol Ther. 2000. PMID: 10933938
-
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.Mol Ther. 2001 Sep;4(3):192-200. doi: 10.1006/mthe.2001.0442. Mol Ther. 2001. PMID: 11545609
-
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.Gene Ther. 2008 Jun;15(11):870-5. doi: 10.1038/gt.2008.71. Epub 2008 Apr 24. Gene Ther. 2008. PMID: 18432276 Review.
-
AAV-mediated gene transfer for hemophilia.Ann N Y Acad Sci. 2001 Dec;953:64-74. doi: 10.1111/j.1749-6632.2001.tb11361.x. Ann N Y Acad Sci. 2001. PMID: 11795424 Review.
Cited by
-
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.J Clin Invest. 2004 Apr;113(7):1025-31. doi: 10.1172/JCI20106. J Clin Invest. 2004. PMID: 15057309 Free PMC article.
-
The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.Trans Am Clin Climatol Assoc. 2009;120:331-59. Trans Am Clin Climatol Assoc. 2009. PMID: 19768188 Free PMC article.
-
A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.J Virol. 2009 Dec;83(24):12738-50. doi: 10.1128/JVI.01441-09. Epub 2009 Oct 7. J Virol. 2009. PMID: 19812149 Free PMC article.
-
Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy.Nat Biomed Eng. 2019 Oct;3(10):806-816. doi: 10.1038/s41551-019-0431-2. Epub 2019 Jul 22. Nat Biomed Eng. 2019. PMID: 31332341 Free PMC article.
-
Immune Response Mechanisms against AAV Vectors in Animal Models.Mol Ther Methods Clin Dev. 2019 Dec 25;17:198-208. doi: 10.1016/j.omtm.2019.12.008. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2019. PMID: 31970198 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical